Method of delivering a somatostatin compound into a lumen of the intestinal tract using a swallowable drug delivery device
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
1. A method for delivering a somatostatin compound to a patient in need thereof, the method comprising:
swallowing an enclosure having an interior, a delivery means, and a somatostatin preparation coupled to the delivery means, the somatostatin preparation comprising a therapeutically effective dose of a somatostatin compound comprising somatostatin or a somatostatin analogue, the delivery means having a first configuration and a second configuration, the preparation being contained within the interior in the first configuration and advanced out of the interior and into a gastro-intestinal (GI) lumen wall in the second configuration to deliver the somatostatin preparation into the GI lumen wall, the enclosure protecting the somatostatin preparation from degradation by GI fluids, the somatostatin preparation supplied in the enclosure in a form which can be delivered from the enclosure into the wall of GI lumen by the application of force on the preparation; and
triggering the delivery means responsive to a condition in the GI lumen to deliver the somatostatin preparation from the enclosure into the wall of the GI lumen.
2. The method of claim 1 , wherein the GI lumen is the small intestine.
3. The method of claim 1 , wherein the condition is a selected pH.
4. The method of claim 3 , wherein the pH is above about 7.1.
5. The method of claim 1 , wherein a weight percent of somatostatin compound in the preparation is in a range between about 0.3 to 8%.
6. The method of claim 1 , wherein a dose of somatostatin compound in the somatostatin preparation is in a range from about 50 to 600 mg.
7. The method of claim 6 , wherein the dose of somatostatin or somatostatin compound in the somatostatin preparation is in a range from about 50 to 100 mg.
8. The method of claim 1 , wherein the somatostatin analogue is octreotide.
9. The method of claim 8 , wherein a dose of octreotide in the preparation is in a range from about 10 to 100 μg.
10. The method of claim 9 , wherein the dose of octreotide in the preparation is in a range from about 20 to 80 μg.
11. The method of claim 1 , wherein the somatostatin preparation comprises at least one pharmaceutical excipient.
12. The method of claim 11 , wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.
13. The method of claim 1 , further comprising retaining the somatostatin preparation within the GI lumen wall after insertion.
14. The method of claim 13 , wherein retaining comprises anchoring a portion of the somatostatin preparation in GI lumen wall tissue.
15. The method of claim 1 , wherein delivering the somatostatin preparation comprises applying a force to the somatostatin preparation.
16. The method of claim 15 , wherein the somatostatin preparation is advanced completely into the GI lumen wall by such application of force.
17. The method of claim 15 , wherein the somatostatin preparation is advanced through the GI lumen wall by such application of force.
18. The method of claim 15 , wherein the force is a mechanical force applied to a surface of somatostatin preparation.
19. The method of claim 1 , wherein the somatostatin preparation produces a long-term release of the somatostatin compound.
20. The method of claim 19 , wherein the long term release is over a period of about 6 to 24 hours.
21. The method of claim 1 , further comprising:
using the dose of delivered somatostatin compound to treat a somatostatin responsive condition in a patient.
22. The method of claim 21 , wherein the somatostatin responsive condition is acromegaly.
23. The method of claim 21 , wherein the somatostatin responsive condition is diarrhea associated with carcinoid syndrome, or diarrhea associated with vasoactive intestinal peptide-secreting tumors.